The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes

Mali Barbi, Della Makower, Joseph A. Sparano

Research output: Contribution to journalReview articlepeer-review

Abstract

Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER-2 negative breast cancer. We review the results of trials establishing the clinical utility of several commercially available gene expression assays.

Original languageEnglish (US)
JournalTherapeutic Advances in Medical Oncology
Volume13
DOIs
StatePublished - 2021
Externally publishedYes

Keywords

  • breast cancer
  • chemotherapy
  • gene expression profiling
  • hormone receptor-positive breast cancer
  • hormone therapy

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes'. Together they form a unique fingerprint.

Cite this